Vaccinia Virus News and Research

RSS

The vaccinia virus is the "live virus" used in the smallpox vaccine. It is a "pox"-type virus related to smallpox. When given to humans as a vaccine, it helps the body to develop immunity to smallpox. The smallpox vaccine does not contain the smallpox virus and it cannot cause smallpox.

Oncolytic virus alerts the immune system to attack tumors

A new UC San Francisco study has shown that a cancer-killing virus currently in clinical trials may function as a cancer vaccine - in addition to killing some cancer cells directly, the virus alerts the immune system to the presence of a tumor, triggering a powerful, widespread immune response that kills cancer cells far outside the virus-infected region.

14 Feb 2018

Study: Investigational Ebola vaccine regimen induced immune response that persisted for one year

A two-vaccine regimen intended to protect against Ebola virus disease induced an immune response that persisted for approximately one year in healthy adult volunteers, according to results from a Phase 1 clinical trial published in the March 14th issue of the Journal of the American Medical Association.

15 Mar 2017

New study examines immune responses to Ebola vaccines at one year after immunization

Immune responses to Ebola vaccines at one year after vaccination are examined in a new study appearing in the March 14 issue of JAMA.

14 Mar 2017

Scientists discover critical role of biological molecule in protecting against infection

Scientists have discovered that a biological molecule important in cell growth (STAT3) is also critical in protecting us against infection - so much so that we would be unable to fight the common flu virus without it.

26 Jan 2017

Two Ebola vaccine candidates show promise in clinical trial

An immunization regimen using two Ebola vaccine candidates was safe and well-tolerated and induced an immune response in healthy adult volunteers in a Phase 1 clinical trial.

20 Apr 2016

TG4010 vaccine promising in advanced NSCLC

Addition of the TG4010 vaccine to first-line chemotherapy improves outcomes in patients with advanced non-small-cell lung cancer, show the results of a placebo controlled trial.

19 Jan 2016

New vaccine shows promise against Middle East respiratory syndrome in dromedary camels

An international research project with the involvement of Universitat Autònoma de Barcelona and the Animal Health Research Centre (IRTA-CReSA), has designed a vaccine shown to be effective in protecting dromedaries against the coronavirus (CoV) that causes Middle East respiratory syndrome (MERS).

18 Dec 2015

Planning for first clinical trial of MERS-CoV vaccine candidate now underway

Researchers from Ludwig-Maximilians-Universitaet in Munich have demonstrated, in a preclinical setting, the protective effect of a candidate vaccine directed against the coronavirus that causes Middle East Respiratory Syndrome. Planning for the first clinical trial is now underway.

22 Jun 2015

Viruses designed to kill cancer cells could boost effectiveness of chemotherapy to arms, legs

Viruses designed to target and kill cancer cells could boost the effectiveness of chemotherapy to the arms and legs and help avoid amputation, a new study reports.

22 Jul 2014

NIH study could offer clues for developing new antiviral treatments

A National Institutes of Health study reports that a rare genetic disease, while depleting patients of infection-fighting antibodies, may actually protect them from certain severe or recurrent viral infections.

10 Apr 2014

Scientists discover potential cure for triple negative breast cancer

Scientists have discovered a potential cure for one of the most aggressive and least treatable forms of breast cancer called "triple negative breast cancer." In laboratory experiments involving human cancer cells, scientists used a virus similar to the one that helped eradicate smallpox to coax cancer cells to produce a protein which makes them susceptible to radioactive iodine.

31 Jan 2014

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.

12 Dec 2013

Transgene welcomes SillaJen’s intention to acquire Jennerex

Transgene SA (Paris:TNG) said today that it welcomed the announcement by SillaJen, Inc. of its intention to acquire Jennerex, Inc. and has consequently given its consent to the definitive merger agreement.

26 Nov 2013

Specific antibody patterns predict schizophrenia risk

The presence of antibodies to multiple foods and infectious agents is a risk marker for new-onset schizophrenia, a case-control study suggests.

23 Oct 2013

New method to display viral DNA in host cells at single-molecule resolution

The medical, humanitarian and economical impact of viral diseases is devastating to humans and livestock. There are no adequate therapies available against most viral diseases, largely because the mechanisms by which viruses infect cells are poorly known.

17 Oct 2013

MIT engineers develop nanoparticles that deliver cancer vaccines to lungs

Many viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs, gastrointestinal tract and reproductive tract. To help fight these pathogens, scientists are working on vaccines that can establish a front line of defense at mucosal surfaces.

26 Sep 2013

Researchers produce first genome-wide investigation of cap-independent translation

Because of their central importance to biology, proteins have been the focus of intense research, particularly the manner in which they are produced from genetically coded templates-a process commonly known as translation. While the general mechanism of translation has been understood for some time, protein synthesis can initiate by more than one mechanism. One of the least well understood mechanisms is known as cap-independent translation.

17 Jun 2013

Researchers evaluate Pexa-Vec to slow progression of liver cancer

As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma or liver cancer. Pexa-Vec is a genetically engineered virus that is used in the smallpox vaccine.

10 Apr 2013

Clinical data of two Transgene products to be presented at EASL Conference

Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and infectious diseases, today announced that favourable pre-clinical and clinical data on two Transgene products - TG1050 and TG4040 to treat chronic hepatitis B and chronic hepatitis C, respectively - will be presented in oral presentations at this year's European Association for the Study of the Liver Conference (Amsterdam, Netherlands, April 24-28, 2013).

9 Apr 2013

Finding solutions to protect U.S. troops against invisible killers

A Saint Louis University researcher has received a contract worth up to $980,000 to see if two cancer medications have the potential of protecting U.S. troops from biological agents that could be unleashed during an attack.

4 Apr 2013